Heat expands cohorts in early stage bladder cancer trial

|About: Heat Biologics, Inc. (HTBX)|By:, SA News Editor

Heat Biologics' (HTBX) Dose Escalation Committee approves the expansion of the first cohort to the full enrollment of nine patients in its Phase 1/2 study of HS-410 (vesigenpumatucel-L) for the treatment of bladder cancer after the first three patients exhibited no serious adverse events. The trial will eventually enroll 93 patients after transurethral resection of bladder tumor (TURBT) and bacillus Calmette-Guerin (BCG).

The Phase 1 portion evaluates the safety of two doses of HS-410 in bladder cancer patients. Phase 2 evaluates the effectiveness of a vaccination with HS-410 in extending the time of disease recurrence compared to placebo.